Factory Mutual Insurance Co. Buys New Stake in Smith & Nephew SNATS, Inc. $SNN

Factory Mutual Insurance Co. purchased a new position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 27,747 shares of the medical equipment provider’s stock, valued at approximately $1,007,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its stake in shares of Smith & Nephew SNATS by 321.6% during the 2nd quarter. Bank of Montreal Can now owns 3,429,829 shares of the medical equipment provider’s stock worth $105,056,000 after acquiring an additional 2,616,301 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Smith & Nephew SNATS by 6,663.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,210,655 shares of the medical equipment provider’s stock worth $37,082,000 after purchasing an additional 1,192,755 shares during the period. ABC Arbitrage SA boosted its position in Smith & Nephew SNATS by 1,063.4% during the second quarter. ABC Arbitrage SA now owns 898,635 shares of the medical equipment provider’s stock worth $27,525,000 after purchasing an additional 821,393 shares in the last quarter. Todd Asset Management LLC purchased a new position in Smith & Nephew SNATS during the third quarter worth approximately $26,319,000. Finally, Goldman Sachs Group Inc. grew its holdings in Smith & Nephew SNATS by 49.2% in the first quarter. Goldman Sachs Group Inc. now owns 1,771,401 shares of the medical equipment provider’s stock valued at $50,255,000 after purchasing an additional 583,809 shares during the period. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Smith & Nephew SNATS Price Performance

Shares of NYSE SNN opened at $35.68 on Friday. The firm has a 50-day simple moving average of $33.70 and a 200-day simple moving average of $34.91. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a 52 week low of $23.91 and a 52 week high of $38.79.

Analyst Ratings Changes

Several brokerages have recently weighed in on SNN. Wall Street Zen raised Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 10th. Royal Bank Of Canada lowered shares of Smith & Nephew SNATS from an “outperform” rating to a “sector perform” rating in a report on Monday, December 15th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a report on Wednesday, January 21st. Kepler Capital Markets raised shares of Smith & Nephew SNATS to a “strong-buy” rating in a research note on Monday, November 17th. Finally, Canaccord Genuity Group reduced their price target on shares of Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating for the company in a research report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Smith & Nephew SNATS presently has a consensus rating of “Hold” and an average price target of $35.75.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.